A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor

Trial Profile

A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs Everolimus (Primary) ; Exemestane (Primary) ; Ribociclib (Primary)
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TRINITI-1
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 05 Apr 2017 Results of phase I (n=17) assessing tolerability and pharmacokinetics, presented at the 108th Annual Meeting of the American Association for Cancer Research
    • 23 Feb 2017 Planned End Date changed from 1 May 2018 to 25 May 2018.
    • 23 Feb 2017 Planned primary completion date changed from 1 May 2018 to 25 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top